Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243013 | 0.72 | THRB (0.38) | SMN1; SMN2GAATHRBMAPTHPGDS | |
| SCHEMBL3246092 | 0.69 | MEN1 (0.39) | SMN1; SMN2THRBMAPTGPR119 | |
| SCHEMBL3247572 | 0.69 | MEN1 (0.36) | SMN1; SMN2GAATHRBMAPTGPR119 | |
| SCHEMBL3247577 | 0.66 | MEN1 (0.36) | PRMT5WDR77MAPTGPR119JAK2 | |
| SCHEMBL23910164 | 0.63 | NR1H2 (0.42) | SMN1; SMN2PRMT5WDR77MAPT | |
| SCHEMBL23860091 | 0.63 | NR1H2 (0.42) | SMN1; SMN2PRMT5WDR77MAPT | |
| SCHEMBL2328081 | 0.62 | HPGDS (0.49) | THRBMAPTHPGDSGPR119JAK2 | |
| SCHEMBL23249978 | 0.62 | RECQL (0.47) | SMN1; SMN2THRBPRMT5WDR77MAPT | |
| SCHEMBL25384043 | 0.61 | ABHD6 (0.50) | — | |
| SCHEMBL2148636 | 0.61 | SMN1; SMN2 (0.49) | SMN1; SMN2USP30JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799674-B1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | SMN1; SMN2 2971/4885GAA 3929/4885THRB 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.